----
Current ValuationThe current P/E ratio is 13.45, within the reasonable range, cheaper than 59.21% of the time in the past 3 years, and the industry ranks 8/74, the industry Median --.
13.45xP/E
$178.69Stock price
$13.28Earnings per share
13.45xP/E
Stock price$178.69Earnings per share$13.28
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 14.06x
- Typical range
- 11.87x–16.05x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
07142128
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
CIUSCigna | 11.14x | 11.91% | $71.48B |
FMSUSFresenius Medical Care | 11.85x | 14.95% | $12.90B |
DVAUSDaVita | 13.45x | 48.02% | $11.40B |
AVAHUSAveanna Healthcare | 10.00x | 31.53% | $2.75B |
MDUSPediatrix Medical | 12.07x | 1.36% | $2.11B |
AMNUSAMN Healthcare Services | 13.52x | 174.65% | $1.42B |
SBCUSSBC Medical | 10.68x | 6.50% | $523.49M |
SRTAUSStrata Critical Medical | 10.40x | 61.46% | $418.45M |
NIVFUSNewGenIvf | 0.03x | 97.79% | $290.99K |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
